Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCR-engineered T Cells Recognizing KRAS Mutations in Advanced Solid Tumors
NCT06218914Phase 1Recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2024
- Primary completion
- Aug 2027
- Modality
- Prophylactic Vaccines, Gene Silencing, CRISPR-Cas9
- Countries
- 1
01
Overview
Phase 1, open-label trial of NT-112 and AZD0240 in solid tumor, non-small cell lung cancer (NSCLC), colorectal carcinoma (CRC) and 2 more (2 arms), sponsored by AstraZeneca. Primary endpoints: Safety and Tolerability at 2 years and Maximum Tolerated Dose at 28 days. Started Mar 2024; status: recruiting.
02
Drugs
NT-112AZD0240
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)colorectal carcinoma (CRC)pancreatic ductal adenocarcinoma (PDAC)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT06218914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06218914.